Letters
Overspending on cancer drug vials
The drug industry can help reduce cancer drug costs
BMJ 2016; 352 doi: https://doi.org/10.1136/bmj.i1551 (Published 21 March 2016) Cite this as: BMJ 2016;352:i1551
- Peter J Gilbar, consultant pharmacist and senior lecturer1 2,
- Margot J Tannock, senior pharmacist1
- 1Cancer and Palliative Care Services, Toowoomba Hospital, Toowoomba, Qld 4350, Australia
- 2School of Medicine, University of Queensland, Qld, Australia
- peter.gilbar{at}health.qld.gov.au
Bach and colleagues’ article is particularly relevant because cancer drug expenditure is of major concern.1 Increasing the range of vial strengths is one way to contain spending. Unfortunately vial sharing is not always feasible. In Australia, many cancer centres outsource cancer drug manufacturing to accredited commercial suppliers, who, for high …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.